glp 1 drugs news GLP-1 weight loss leave users low on key nutrients, study finds GLP-1 Receptor Agonist Shortage: Challenges

Revised July 2023

50 Danuglipron showed a dose-proportional increase in exposure at steady state with reductions in the mean daily glucose, fasting plasma glucose, and glycated hemoglobin (HbA1c) compared to baseline and placebo

The introduction of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has emerged as a pivotal treatment option for obesity and diabetes, demonstrating efficacy in blood glucose management, weight reduction, cardiovascular disease prevention, and kidney health improvement [10]

Suter, Megan E

Overall, GLP-1RAs provide a highly effective and well-tolerated treatment option to help individuals with obesity achieve and maintain body weight reductions of 510%, thereby improving weight-related complications in addition to weight loss